Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Revolution Medicines ( (RVMD) ) is now available.
On October 16, 2025, Revolution Medicines announced that the U.S. FDA granted them a non-transferrable voucher for their RAS(ON) multi-selective inhibitor, daraxonrasib, under the National Priority Voucher pilot program. This development is significant for the company as it enhances their market positioning and could accelerate the regulatory review process, potentially benefiting stakeholders by expediting the availability of their innovative cancer treatment.
The most recent analyst rating on (RVMD) stock is a Buy with a $72.00 price target. To see the full list of analyst forecasts on Revolution Medicines stock, see the RVMD Stock Forecast page.
Spark’s Take on RVMD Stock
According to Spark, TipRanks’ AI Analyst, RVMD is a Neutral.
Revolution Medicines has a moderate overall score primarily due to financial challenges such as declining revenues and persistent net losses, common in biotech firms. The technical analysis indicates a bearish trend, and the valuation remains unattractive with a negative P/E ratio. However, the positive strides in the RAS(ON) inhibitor pipeline and strong liquidity position partially offset these challenges, as highlighted in the recent earnings call.
To see Spark’s full report on RVMD stock, click here.
More about Revolution Medicines
Revolution Medicines, Inc. operates in the biotechnology industry, focusing on developing targeted therapies for cancer treatment, with a particular emphasis on RAS pathway inhibitors.
Average Trading Volume: 2,008,878
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.29B
Learn more about RVMD stock on TipRanks’ Stock Analysis page.